XBiotech’s vilamakitug met the Phase II TASKIN trial’s 12-month survival criterion in refractory metastatic colorectal cancer, with an exploratory survival signal in right-sided tumours.
Written By: Anshu Gupta, PharmD
Reviewed By: Pharmacally Editorial Team
XBiotech reported positive final efficacy results on October 19, 2026, from the Phase II portion of the investigator-sponsored TASKIN trial (NCT05201352), evaluating vilamakitug (XB2001; Natrunix), an investigational monoclonal antibody targeting interleukin-1 alpha (IL-1α), in patients with refractory metastatic colorectal cancer (mCRC).
The randomized, multicentre study evaluated vilamakitug in combination with trifluridine/tipiracil (TAS-102), with or without bevacizumab, against placebo plus standard chemotherapy. The trial was funded by the French National Cancer Institute (INCa) and sponsored by Centre Georges-François Leclerc in Dijon, France.
Prespecified 12-Month Survival Criterion Achieved
The Phase II study met its prespecified primary efficacy success criterion under a Simon two-stage design. At the 12-month landmark, 49 of 80 evaluable patients (61.3%) in the vilamakitug arm were alive, exceeding the protocol-defined threshold of at least 42 survivors. In the control arm, 44 of 79 evaluable patients (55.7%) were alive.
The absolute difference in 12-month survival was 5.6 percentage points in favour of vilamakitug. However, meeting the prespecified efficacy criterion does not establish a statistically significant overall survival advantage over control. The result supports further investigation rather than a definitive conclusion about comparative efficacy.
Overall Efficacy Findings Remain Inconclusive
Secondary efficacy outcomes showed numerical differences between treatment groups, but the overall comparisons did not reach statistical significance.
Median progression-free survival (PFS) was 5.9 months with vilamakitug compared with 5.6 months in the control arm. The respective 12-month PFS rates were 25.0% and 21.0% (log-rank p = 0.42). XBiotech also reported that the PFS curves began to separate after month seven. This pattern may warrant further evaluation, but the reported comparison does not establish an overall PFS benefit.
The 12-month time-to-strategy-failure (TSF) rate was 31.2% with vilamakitug versus 20.3% with control (log-rank p = 0.17). TSF assesses how long the overall treatment strategy remains viable. The numerical difference favoured vilamakitug, although the result was not statistically significant.
Treatment adherence findings showed mean compliance of 96.4% for trifluridine/tipiracil. Permanent discontinuation of vilamakitug or placebo was reported in 1.3% of patients. These measures provide information about treatment feasibility but do not establish the combination’s overall safety profile. Detailed adverse-event data are needed to characterize its tolerability and risks.
Exploratory Analysis Identifies a Signal in Right-Sided Tumours
A prospective exploratory analysis involving 37 patients with right-sided (proximal) primary tumours identified statistically significant differences favouring vilamakitug in overall survival and TSF.
Through 12 months, vilamakitug was associated with a 62% relative reduction in the hazard of death compared with control (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.14–0.99; Cox p = 0.047; log-rank p = 0.038). The analysis also reported a 61% relative reduction in the hazard of treatment-strategy failure (HR, 0.39; 95% CI, 0.18–0.85; Cox p = 0.017; log-rank p = 0.014).
XBiotech associated the subgroup findings with elevated baseline tumour IL-1α expression, providing a potential biological rationale for further investigation. However, the small subgroup and exploratory nature of the analysis limit the conclusions that can be drawn. Neither tumour location nor IL-1α expression has been established by these results as a validated predictor of treatment benefit.
Mechanism and Development Outlook
Vilamakitug is a human monoclonal antibody designed to target IL-1α, a mediator involved in inflammatory signalling. XBiotech’s therapeutic approach seeks to target biological processes that may contribute to malignant cell growth and tumour progression.
TASKIN investigated whether adding IL-1α inhibition to established chemotherapy could improve outcomes in patients with refractory metastatic disease. Following the reported results, XBiotech indicated that the findings could guide further development towards registrational studies, with particular interest in patients with right-sided primary tumours. This remains a development intention, not evidence that the treatment is ready for regulatory approval.
Clinical Interpretation
TASKIN provides a preliminary efficacy signal for vilamakitug in refractory mCRC. Meeting the prespecified 12-month survival criterion represents a positive trial milestone, but the 5.6-percentage-point difference in survival and the nonsignificant overall PFS and TSF comparisons limit claims of comparative benefit.
The right-sided tumour analysis offers a rationale for further investigation, but confirmation in larger studies is necessary. Future research should clarify the reproducibility of the subgroup findings, assess whether tumour location or IL-1α expression can guide patient selection, and provide a comprehensive evaluation of safety.
Reference
XBiotech Inc. XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer. October 19, 2026.
Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine (TASKIN), ClinicalTrials.gov ID NCT05201352
About the Writer
Anshu Gupta (LinkedIn) is a PharmD professional and healthcare writer with interests in clinical research, pharmacovigilance, regulatory affairs, and medical writing. She has presented research at academic conferences and completed certifications in Good Clinical Practice (GCP), ICH-GCP, and drug safety. Passionate about clinical trials and evidence-based medicine, she is committed to translating scientific evidence into accurate, reliable, and accessible healthcare content.